RhumbLine Advisers’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-89,339
| Closed | -$6.08M | – | 3081 |
|
|
2022
Q3 | $6.08M | Buy |
89,339
+15,894
| +22% | +$877K | 0.01% | 1123 |
|
|
2022
Q2 | $2.35M | Buy |
73,445
+8,466
| +13% | +$248K | ﹤0.01% | 1687 |
|
|
2022
Q1 | $2.25M | Buy |
64,979
+1,876
| +3% | +$56.1K | ﹤0.01% | 1755 |
|
|
2021
Q4 | $1.85M | Buy |
63,103
+236
| +0.4% | +$7.31K | ﹤0.01% | 1928 |
|
|
2021
Q3 | $1.6M | Buy |
62,867
+1,877
| +3% | +$55.2K | ﹤0.01% | 2019 |
|
|
2021
Q2 | $2.14M | Buy |
60,990
+757
| +1% | +$29.6K | ﹤0.01% | 1920 |
|
|
2021
Q1 | $2.45M | Sell |
60,233
-3,324
| -5% | -$153K | ﹤0.01% | 1818 |
|
|
2020
Q4 | $2.75M | Sell |
63,557
-2,576
| -4% | -$127K | ﹤0.01% | 1684 |
|
|
2020
Q3 | $3.65M | Sell |
66,133
-3,739
| -5% | -$238K | 0.01% | 1350 |
|
|
2020
Q2 | $4.41M | Sell |
69,872
-15,215
| -18% | -$1.04M | 0.01% | 1285 |
|
|
2020
Q1 | $4.35M | Buy |
85,087
+2,743
| +3% | +$184K | 0.01% | 1110 |
|
|
2019
Q4 | $6.55M | Buy |
82,344
+3,924
| +5% | +$233K | 0.01% | 1092 |
|
|
2019
Q3 | $3.81M | Buy |
78,420
+671
| +0.9% | +$35K | 0.01% | 1339 |
|
|
2019
Q2 | $4.09M | Buy |
77,749
+7,220
| +10% | +$415K | 0.01% | 1311 |
|
|
2019
Q1 | $3.73M | Buy |
70,529
+4,048
| +6% | +$199K | 0.01% | 1349 |
|
|
2018
Q4 | $2.73M | Buy |
66,481
+21,302
| +47% | +$798K | 0.01% | 1460 |
|
|
2018
Q3 | $1.72M | Sell |
45,179
-3,439
| -7% | -$152K | ﹤0.01% | 1741 |
|
|
2018
Q2 | $2.2M | Buy |
48,618
+12,622
| +35% | +$575K | ﹤0.01% | 1628 |
|
|
2018
Q1 | $1.74M | Sell |
35,996
-1,014
| -3% | -$56.6K | ﹤0.01% | 1688 |
|
|
2017
Q4 | $1.46M | Sell |
37,010
-5,731
| -13% | -$214K | ﹤0.01% | 1778 |
|
|
2017
Q3 | $1.33M | Buy |
42,741
+940
| +2% | +$26.4K | ﹤0.01% | 1843 |
|
|
2017
Q2 | $1.14M | Buy |
41,801
+22,670
| +118% | +$675K | ﹤0.01% | 1880 |
|
|
2017
Q1 | $705K | Buy |
19,131
+2,089
| +12% | +$52.6K | ﹤0.01% | 2096 |
|
|
2016
Q4 | $246K | Buy |
17,042
+4,156
| +32% | +$73K | ﹤0.01% | 2588 |
|
|
2016
Q3 | $297K | Buy |
12,886
+1,215
| +10% | +$23.2K | ﹤0.01% | 2489 |
|
|
2016
Q2 | $194K | Buy |
+11,671
| New | +$235K | ﹤0.01% | 2756 |
|
|
2016
Q1 | – | Sell |
-6,255
| Closed | -$202K | – | 2999 |
|
|
2015
Q4 | $202K | Buy |
+6,255
| New | +$271K | ﹤0.01% | 2792 |
|
Other funds holding GBT
RhumbLine Advisers's GBT Position: Q4 2022 in Review
RhumbLine Advisers sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 89,339 shares — an estimated $6.08M sold.
RhumbLine Advisers first reported a position in GBT in Q4 2015 and held it in 27 quarters. The position peaked at $6.55M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- RhumbLine Advisers reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- RhumbLine Advisers sold 89,339 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $6.08M.
- RhumbLine Advisers first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 27 quarters.
- RhumbLine Advisers's Global Blood Therapeutics, Inc. position peaked at $6.55M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on RhumbLine Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.